Targeting the chromatin binding of exportin-1 disrupts NFAT and T cell activation
- 25 March 2024
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (10) , 1260-1271
Abstract
Exportin-1 (XPO1/CRM1) plays a central role in the nuclear-to-cytoplasmic transport of hundreds of proteins and contributes to other cellular processes, such as centrosome duplication. Small molecules targeting XPO1 induce cytotoxicity, and selinexor was approved by the Food and Drug Administration in 2019 as a cancer chemotherapy for relapsed multiple myeloma. Here, we describe a cell-type-dependent chromatin-binding function for XPO1 that is essential for the chromatin occupancy of NFAT transcription factors and thus the appropriate activation of T cells. Additionally, we establish a class of XPO1-targeting small molecules capable of disrupting the chromatin binding of XPO1 without perturbing nuclear export or inducing cytotoxicity. This work defines a broad transcription regulatory role for XPO1 that is essential for T cell activation as well as a new class of XPO1 modulators to enable therapeutic targeting of XPO1 beyond oncology including in T cell-driven autoimmune disorders.Keywords
Funding Information
- Division of Intramural Research (AI171104)
- Dr. Ralph and Marian Falk Medical Research Trust
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007250, T32GM135081, T32GM007250, T32GM007250)
- The Harrington Discovery Institute accelerates promising discoveries into medicines for unmet needs
- U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (F30HD096784)
This publication has 53 references indexed in Scilit:
- Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and SelectivityChemBioChem, 2021
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsLeukemia, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Structural basis for leucine-rich nuclear export signal recognition by CRM1Nature, 2009
- The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studiesBioorganic & Medicinal Chemistry Letters, 2003
- The role of NF-AT transcription factors in T cell activation and differentiation11We dedicate this review to Prof. Dr. Rigomar Rieger (Gatersleben), a great scientist and man, on the occasion of his 70th birthday. One of us (E.S.) had the pleasure of working in his department.Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- Inhibitors of NF-κB and AP-1 Gene Expression: SAR Studies on the Pyrimidine Portion of 2-Chloro-4-trifluoromethylpyrimidine-5-[N-(3‘,5‘-bis(trifluoromethyl)phenyl)carboxamide]Journal of Medicinal Chemistry, 2000
- NF-AT activation requires suppression of Crm1-dependent export by calcineurinNature, 1999
- 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3‘,5‘-bis(trifluoromethyl)phenyl)- carboxamide: A Potent Inhibitor of NF-κB- and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial ChemistryJournal of Medicinal Chemistry, 1998
- A novel inhibitor of nuclear factor-κB and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivoTransplantation Proceedings, 1997